• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症合并感染患者住院发病率和结局的变化趋势:一项全国性分析。

Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Infection: A Nationwide Analysis.

机构信息

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

出版信息

J Natl Compr Canc Netw. 2017 Apr;15(4):466-472. doi: 10.6004/jnccn.2017.0046.

DOI:10.6004/jnccn.2017.0046
PMID:28404757
Abstract

Patients with cancer have several risk factors for infection (CDI), but the impact of CDI on outcomes in this population needs elucidation. We analyzed the incidence of CDI and its impact on outcomes in patients with cancer using the National Hospital Discharge Survey (NHDS) database from 2001 to 2010. Diagnosis codes were used to identify patients with cancer and CDI events. Demographics, diagnoses, length of stay (LOS), and discharge information were abstracted. Multivariate linear and logistic regression models with weighted analysis were conducted to study CDI incidence and CDI-associated outcomes. Analyses were performed using SAS version 9.4. During the 10-year study period, 20.1 million discharges had a cancer diagnosis. CDI developed in 1.09% of patients with cancer versus 0.77% of patients without cancer (adjusted odds ratio [aOR], 1.28; 95% CI, 1.28-1.29; <.001). The incidence of CDI in patients with cancer increased during the 10-year study period (64.7 per 10,000 discharges in 2001-2002 to 109.1 in 2009-2010; <.001). In multivariable analysis, compared with patients with cancer without CDI, patients with cancer and CDI had a longer mean LOS (5.67 days; 95% CI, 5.39-5.94) and higher rates of in-hospital mortality (aOR, 1.18; 95% CI, 1.16-1.20) and discharge to a care facility (aOR, 1.74; 95% CI, 1.72-1.75; all <.001). In this national database, CDI incidence increased significantly in patients with cancer over the study period and was associated with prolonged hospitalization, increased mortality, and discharge to a care facility. Despite increased attention, CDI remained a serious infection and merits appropriate prevention and management.

摘要

患有癌症的患者存在多种感染(CDI)的风险因素,但 CDI 对该人群结局的影响仍需要阐明。我们利用 2001 年至 2010 年的全国医院出院调查(NHDS)数据库分析了癌症患者中 CDI 的发生率及其对结局的影响。采用诊断代码来识别癌症患者和 CDI 事件。提取患者的人口统计学、诊断、住院时间(LOS)和出院信息。采用加权分析的多变量线性和逻辑回归模型来研究 CDI 发生率和 CDI 相关结局。采用 SAS 版本 9.4 进行分析。在 10 年的研究期间,有 2010 万出院患者患有癌症。患有癌症的患者中 CDI 发生率为 1.09%,而无癌症的患者中为 0.77%(校正优势比 [aOR],1.28;95%置信区间 [CI],1.28-1.29;<0.001)。在 10 年的研究期间,癌症患者中 CDI 的发生率呈上升趋势(2001-2002 年为每 10000 出院患者 64.7 例,2009-2010 年为 109.1 例;<0.001)。在多变量分析中,与无 CDI 的癌症患者相比,患有癌症且合并 CDI 的患者 LOS 更长(平均 5.67 天;95%CI,5.39-5.94),院内死亡率更高(aOR,1.18;95%CI,1.16-1.20),且更倾向于出院至护理机构(aOR,1.74;95%CI,1.72-1.75;均<0.001)。在这个全国性数据库中,研究期间癌症患者的 CDI 发生率显著增加,与住院时间延长、死亡率增加和出院至护理机构相关。尽管受到了更多关注,但 CDI 仍是一种严重感染,需要进行适当的预防和管理。

相似文献

1
Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Infection: A Nationwide Analysis.癌症合并感染患者住院发病率和结局的变化趋势:一项全国性分析。
J Natl Compr Canc Netw. 2017 Apr;15(4):466-472. doi: 10.6004/jnccn.2017.0046.
2
The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.炎症性肠病成年住院患者艰难梭菌感染的发病率及转归
Scand J Gastroenterol. 2017 Nov;52(11):1240-1247. doi: 10.1080/00365521.2017.1362466. Epub 2017 Aug 6.
3
Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals.在美国社区医院中,被诊断患有艰难梭菌感染的癌症患者预后较差。
BMC Infect Dis. 2017 Jun 23;17(1):448. doi: 10.1186/s12879-017-2553-z.
4
Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.艰难梭菌感染住院成人的流行病学、结局及死亡预测因素
Intern Emerg Med. 2016 Aug;11(5):657-65. doi: 10.1007/s11739-015-1366-6. Epub 2015 Dec 22.
5
Clostridium difficile infection in patients with chronic kidney disease.艰难梭菌感染与慢性肾脏病患者。
Mayo Clin Proc. 2012 Nov;87(11):1046-53. doi: 10.1016/j.mayocp.2012.05.025.
6
Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database.艰难梭菌感染与住院实体器官移植受者结局的关联:来自2009年全国住院患者样本数据库的结果
Transpl Infect Dis. 2012 Oct;14(5):540-7. doi: 10.1111/j.1399-3062.2012.00761.x. Epub 2012 Jun 22.
7
The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010.2001 - 2010年美国住院成人艰难梭菌感染发病率的上升情况
Am J Infect Control. 2014 Oct;42(10):1028-32. doi: 10.1016/j.ajic.2014.06.011.
8
Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care.2型糖尿病住院患者的艰难梭菌感染及其对发病率、死亡率和住院护理费用的影响。
Diabetes Res Clin Pract. 2016 Jun;116:68-79. doi: 10.1016/j.diabres.2016.04.021. Epub 2016 Apr 24.
9
Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide Inpatient Sample.艰难梭菌感染对肺炎和尿路感染住院患者的影响:一项基于全国住院患者样本的分析
BMC Infect Dis. 2015 Jul 1;15:254. doi: 10.1186/s12879-015-0925-9.
10
National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals.美国社区医院艰难梭菌感染发病率和健康结局的全国年龄组趋势
BMC Infect Dis. 2016 Nov 17;16(1):682. doi: 10.1186/s12879-016-2027-8.

引用本文的文献

1
Bezlotoxumab for the prevention of recurrent infection for patients with cancer.贝佐妥单抗用于预防癌症患者反复感染。
Ann Gastroenterol. 2025 Sep-Oct;38(5):519-525. doi: 10.20524/aog.2025.0994. Epub 2025 Aug 14.
2
Impact of Infection on Chemotherapy in Patients With Primary Ovarian Cancer.感染对原发性卵巢癌患者化疗的影响。
J Korean Med Sci. 2025 Aug 11;40(31):e179. doi: 10.3346/jkms.2025.40.e179.
3
Colon cancer and infection: a not-so-lethal combination?结肠癌与感染:一种并非那么致命的组合?
Proc (Bayl Univ Med Cent). 2024 May 28;37(4):551-552. doi: 10.1080/08998280.2024.2355434. eCollection 2024.
4
Impact of colon cancer on outcomes in hospitalized patients with infection: a national inpatient analysis.结肠癌对感染住院患者预后的影响:一项全国性住院患者分析
Proc (Bayl Univ Med Cent). 2024 May 15;37(4):544-550. doi: 10.1080/08998280.2024.2352817. eCollection 2024.
5
Immune Checkpoint Inhibitors and Infection: What Is the Interplay?免疫检查点抑制剂与感染:它们之间有什么相互作用?
In Vivo. 2023 Nov-Dec;37(6):2409-2420. doi: 10.21873/invivo.13346.
6
Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.癌症患者抗菌药物耐药性的临床结局:多变量模型的系统评价。
BMC Infect Dis. 2023 Apr 18;23(1):247. doi: 10.1186/s12879-023-08182-3.
7
The Role of Bezlotoxumab for the Prevention of Recurrent Infections: A Review of the Current Literature and Paradigm Shift after 2021.贝佐妥单抗在预防复发性感染中的作用:2021年后的当前文献综述及范式转变
Antibiotics (Basel). 2022 Sep 7;11(9):1211. doi: 10.3390/antibiotics11091211.
8
infection in cancer patients receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的癌症患者中的感染
Ann Gastroenterol. 2022 Jul-Aug;35(4):393-399. doi: 10.20524/aog.2022.0722. Epub 2022 Jun 2.
9
Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?肺癌手术患者不良事件报告增加但死亡率降低:在关注医疗质量的时代,这些因素是否相互矛盾?
PLoS One. 2020 Apr 9;15(4):e0231258. doi: 10.1371/journal.pone.0231258. eCollection 2020.
10
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Infection in MODIFY I/II Participants With Cancer.贝佐妥昔单抗对MODIFY I/II期癌症参与者感染相关结局的探索性评估。
Open Forum Infect Dis. 2020 Jan 31;7(2):ofaa038. doi: 10.1093/ofid/ofaa038. eCollection 2020 Feb.